FGFR4 and colonic neoplasm: There is evidence in human colon cancer cell lines, colon tumor xenografts, and FGF19 transgenic mice that blocking selectively the interaction of FGF19 and FGFR4 using an anti-FGF19 monoclonal antibody has a potential pharmacological anti-tumorigenic effect [64].